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A Basic Scientist Perspective
I am honored to serve as an associate editor for Frontiers in Surgery, Heart Surgery Subsection. My
current basic and translational research is in the field of non-coding RNAs, angiogenesis therapy,
and innovative cellular products for cardiovascular therapeutics1. The main translational focus is
on patients with ischemic disease undergoing cardiac and vascular surgery. My team applies basic
science approaches and works on clinical samples and databases with the aim of advancing the
mechanistic understanding of diseases that lead to the need for surgery, to identify potential markers
for patient risk stratification, and to offer surgical patients novel regenerative medicine approaches
that synergize with standard care. I have worked in the cardiovascular field for more than 20 years,
the last 10 years as a next door neighbor to an excellent academic cardiac surgery unit (led by my
co-author)2. Notwithstanding and possibly surprisingly enough, it is only in the last few years that I
started to understand what cardiac surgeons really do in their clinical practice and especially what
kind of research is of relevance to them. For many basic scientists, the translational goals are a bit
naïve and dreamy (“mending a broken heart”) and centered on our own research, developed largely
independently from the potential final users (surgeons and other frontline clinicians), who in our
imagination, should be able to deliver a clinical trial to test our proposed therapeutic remedy based
on work in cells and small animal models. Cardiac surgery is ignored by most of us, who rarely get
in touch with surgeons, especially the rare kind that want to collaborate and offer something more
than spare clinical samples in return for authorship. However, once a good rapport is established,
the possibilities for rewarding collaboration are high and I consider my last years of research among
the most exciting, productive and fun I ever had. The topics for collaboration are large and below
we will discuss some of them. For the readers of this journal, I think it might be interesting to
understandmy perspective as a basic scientist (other basic scientists can of course disagree) on some
issues that might compromise many of these successful interactions. Prejudices, stereotypes, and
ignorance from both ends are not helpful, but unfortunately common. One of the most frequent
is that cardiovascular surgeons are just plumbers and they should not do research. This is something
that I have heard more than once, including from the surgeons themselves. I think this is simply
wrong and based either on ignorance or self-deprecation leading to justification for an “easier”
professional life. Cardiac surgeons are medically qualified and usually some of the most ambitious
clinicians; it is unlikely that working as a surgeon will reduce their intellectual capacities. However,
it is true that the surgeons’ clinical duties are mentally and physically demanding and emergencies
are often managed at antisocial hours. Consequently, when possible the surgeons need to switch
off (this also applies to basic scientists) for their own sanity and for the safety of their next patient.
1http://www.bristol.ac.uk/cardiovascular/people/costanza-emanueli/index.html
2http://www.bristol.ac.uk/cardiovascular/people/gianni-d-angelini/index.html
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This does not mean that they (if they are good academics and
collaborators) will not switch on again in time to complete some
agreed tasks. Moreover, in the academic environment, we should
insist that clinicians (including the junior ones) are given more
opportunities for research-protected time and provided with sup-
port first and foremost from a clinical trial unit. Clinicians, on the
other hand, not infrequently consider their basic science coun-
terparts as belonging to a “B class” in the Faculty of Medicine:
this is not helped by a distinction in remuneration (“clinical and
non-clinical salary scales”) paid to equivalent academic figures.
However, in the changing world, sacrifices comparable to their
clinical colleagues are required from high profile, basic scientists,
including being more and more often “on call” for deadlines
on any sort, in the first instance grant applications, which must
be met and successful to keep the research and labs running.
The basic scientists’ managerial, ethical, and legal responsibilities
have also dramatically increased. To succeed in this increasingly
competitive high-pressure environment, we have to develop the
classical “surgeon thick skin.” I have to come clean and say that
in Bristol, I have never felt “discriminated against” by my sur-
geon collaborators for being a basic scientist. Rather, I feel they
have an admiration for my different kind of work (as I have
for theirs) and welcome my approach to improve their clinical
studies with a healthy mutual respect essential in building fruitful
collaborations. This reciprocal respect does also apply to the other
basic scientists and this culture was proven when my surgeon
co-author teamed up with Professor Andrew Newby (his British
Heart Foundation basic scientist Chair counterpart) to establish
the Bristol Heart Institute3 in 1995. I share the vision of this
research model, which is grounded on the dialog between scien-
tists and clinicians with different research backgrounds, and often
involves leaving our comfort zone (research niche) to explore new
avenues. This is the only way to identify the “real” medical needs
of themoment and design research that has the potential to lead to
clinical applications. I truly believe that only openness, altruism,
and collaboration with like-minded individuals with different
backgrounds will enable us to advance the basic science knowl-
edge required to impact on clinical practice in cardiovascular
surgery.
And Now, Let Us Talk Science!
Zooming in the Human Diseased Heart
Cardiac and vascular surgery offers the opportunity to per-
form fundamental research using a range of samples taken from
patients. Cardiologists can give you some blood and urine (and
rarely myocardial biopsies), but leftover tissue from surgery
can provide precious human material. This offers the oppor-
tunity to develop fundamental research in patients. Functional
studies on cells prepared from human samples might reduce
the use of animal models and concentrate them mainly to
proof-of-principle for efficacy, preclinical safety, and feasibility
studies. We basic scientists are aware of the limitations of ani-
mal models that we use in our “research practice.” It is not
only a common knowledge that sophisticated genetic mouse
3http://www.ukcrcexpmed.org.uk/BristolCVBRU/Pages/FacilityWelcome.aspx
models favor publications in the very top scientific journals
but also true that they do not mimic human pathology well
enough. Moreover, the cost and ethical issues linked to animal
research are growing exponentially. It may be argued that pre-
clinical work on large animals would be a better investment,
but this often requires clinical knowledge, particularly when
conducting interventions modeling the clinical scenario. Exam-
ples of cardiac surgery-relevant animal models are the pedi-
atric ones created by our colleague Professor Caputo (another
associate editor of the Frontiers in Heart Surgery journal), who
has succeeded in mimicking replacement of the pulmonary
artery and valve in young piglets to test the growth capacity
of new tissue engineered conduits (see http://www.bristol.ac.
uk/cardiovascular/people/massimo-caputo/index.html: video 2
JT award and https://www.dropbox.com/s/8l1rc8z2vr1s7h2/JT%
20award%20video%202.m4v).
Omics and System Biology for Defining
Therapeutic Targets and Novel Biomarkers
Cardiac surgery offers the opportunity to analyze in parallel
changes induced by pathologies of the myocardium (or other
organs or tissues, such as heart valves and thoracic vessels) and
biological fluids. Using the new omics possibilities and good bioin-
formatics and systems biology, the opportunity exists not only to
identify new clinically relevant therapeutic targets for validation
in basic science investigations using cells and research animals,
but also to define circulating/urinary biomarkers that provide
information about expressional changes in the heart and link
them to patients’ clinical profiles. In cardiac surgery, the most
needed biomarkers are those enabling prediction of post-surgical
acute complications, like acute kidney injury (1), and long-term
outcomes, such as aneurysm evolution, in many bicuspid aortic
valve surgical patients (2). This knowledge would facilitate moni-
toring and treatment and also allow for better-designed random-
ized clinical trials (RCTs) using the new biomarkers as surrogate
end-points.
Something for the More Optimistic: Gene
Therapy, Stem Cells, and Tissue
Engineering
It is the dream of all basic and clinical scientists to find new
solutions to offer better therapies for patients. The surgeons know
that they can further strive to improve their surgical techniques,
but some of their interventions will remain palliative or not com-
pletely resolutive. Pediatric cardiac surgeons, in particular, suffer
the frustration of having to re-operate on their patients again and
again as they grow to adulthood whereas the conduits andmateri-
als used for the surgical correction do not. The currently available
drugs cannot “regenerate, repair, replace” death or missing parts
of the heart, valves, and blood vessels. Regenerative medicine
was thought to be the answer to fill this gap. For cardiovascular
scientists, this started with angiogenesis gene therapy and went
on with stem cell transplantation with the hope to growth new
blood vessels and even myocardial muscle (3, 4). After the initial
enthusiasm, gene therapy has been in crisis for a while because
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it could not easily deliver the clinical success we all hoped for
(5, 6). We believe that the efforts of basic scientists to improve
viral and non-viral vectors and the newly identified non-coding
RNA targets (especiallymicroRNAs) will “regenerate” interest and
boostmore preclinical and early clinical studies in the area of ther-
apeutic angiogenesis, cardiovascular protection and regeneration,
aneurysms, and vascular graft failure.
Stem cells from different sources have been discovered and
tested in animal models. In the clinic, mostly bone marrow-
derived cells have been trialed, with mixed success (3, 4). Stem
cells and cardiac surgery have not mixed much together so far,
even if small RCTs have been done or are ongoing, including at
our institution (7–11). We have always been fascinated by the
potential of stem cells for cardiovascular therapies and we have
contributed significantly to this field (12–15). At the same time,
we remain a little skeptical that the approaches used so far in
cardiovascular clinical trials, largely based on transplantation of
different types of stem cells administered in a liquid solution
and “left to their destiny” in an hostile environment, will pro-
duce any sustained therapeutic effect. In fact, most of the adult
cell populations considered for clinical use have shown a poor
engraftment capacity and elicit mainly paracrine actions before
dying or being washed out. While we believe that basic stem cell
research including that on cardiac surgery-derived samples should
continue and we are pursuing it extensively, a different focus of
stem cell research is needed to fulfill cardiovascular regeneration
promises.We believe that the new frontier is to use such stem cells
together with clinical-grade matrices to build tissue structures.
This is not only relevant in congenital heart surgery in infants
and children but also for valve replacement in adult patients.
Finally and more futuristically, tissue engineering should deliver
off the shelf myocardial structure to be used to replace large
scars and congenitally lacking myocardium in surgical patients.
This can be corroborated by the recent advances in protocols for
in vitro and even in vivo direct reprograming of fibroblasts to
myocytes (16, 17).
Basic Science “Service” to Cardiac Surgery
Once there is a good team work ethos, basic scientists can also
help modernize and energize the more classical surgical studies
by providing expertise to apply new technologies and refining the
lab analyses to investigate “surgical questions.”
In conclusion, we have focused on our direct experience
of harmonious collaborations between basic scientists and a
cardiac surgery unit. This reflects our vision of a multidis-
ciplinary team capable of bridging novel fundamental science
with clinical practice to synergize the research potential at
both ends. This is the ethos and culture we wish to pass to
the young generation of basic and clinical trainees in Bristol
and elsewhere. The clinicians can identify the medical needs
and priorities, the basic scientists provide the understanding
of the mechanisms of action and “new ideas” and together
we can propose and test new solutions for the benefit of our
patients.
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